Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Terns Pharmaceuticals, Inc. - Common Stock (NQ:TERN)

7.810 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 7.810
Bid (Size) 7.800 (3)
Ask (Size) 8.290 (10)
Prev. Close 7.810
Today's Range 7.810 - 7.810
52wk Range 1.865 - 8.460
Shares Outstanding 61,071,897
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
2 Under-the-Radar Stocks That Could Soar
They could ride the wave of the hottest therapeutic area in the industry. 
Via The Motley Fool
Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025
Webinar to be held on Wednesday, September 3, 2025 at 4:30 p.m. ET 
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire

Performance

YTD
+37.7%
+37.7%
1 Month
+3.3%
+3.3%
3 Month
+83.3%
+83.3%
6 Month
+213.7%
+213.7%
1 Year
-3.6%
-3.6%

More News

Read More
Eli Lilly Shares Tumble as Oral Weight-Loss Hope Falls Short of Lofty Expectations
Via MarketMinute
Topics Economy
Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors
Via Benzinga
Terns (TERN) Q2 Net Loss Narrows 16%
Via The Motley Fool
Topics Intellectual Property
Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Insmed, Tesla, Casey's General Stores And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals to Participate in The Citizens Life Sciences Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grant to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
This Weight Loss Stock Could Skyrocket by 462%, According to Wall Street
Via The Motley Fool
Terns Pharmaceuticals Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45th Annual Healthcare Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Appoints Andrew Gengos as Chief Financial Officer
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Appoints Robert Azelby to Board of Directors
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
Terns Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Terns Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Terns Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Terns Pharmaceuticals, Inc. - Common Stock trade on?
Terns Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Terns Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Terns Pharmaceuticals, Inc. - Common Stock is TERN on the Nasdaq Stock Market
What is the current price of Terns Pharmaceuticals, Inc. - Common Stock?
The current price of Terns Pharmaceuticals, Inc. - Common Stock is 7.810
When was Terns Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Terns Pharmaceuticals, Inc. - Common Stock was at 10/01/25 04:00 PM ET
What is the market capitalization of Terns Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Terns Pharmaceuticals, Inc. - Common Stock is 476.97M
How many shares of Terns Pharmaceuticals, Inc. - Common Stock are outstanding?
Terns Pharmaceuticals, Inc. - Common Stock has 477M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.